 Abnormal processing of the beta-amyloid protein is thought to be an early and causative event in the pathogenesis of Alzheimers disease AD. Immunotherapy targeting beta amyloid Aβ has demonstrated a remarkable capacity to arrest and even reverse elements of AD brain pathology. Intravenous Immunoglobulin IVIg is a medication obtained from the pooled plasma of healthy human blood donors that contains natural anti-amyloid antibodies and exhibits potent central nervous system anti-inflammatory properties. IVIg has been FDA-approved and used for more than 25 years in patients with a variety of immune deficiency and autoimmune diseases and has an established safety record, but is not FDA-approved for the treatment of AD. 